Pricing plans revealed for now COVID-19 treatment
Gilead Sciences announces pre-order pricing plans for coronavirus (COVID-19) treatment, remdesivir, to be offered to patients starting in July. The pharmaceutical company will be donating doses to the U.S. government after authorizing emergency use in May.
Gilead Sciences are set to price remdesivir for U.S. private insurance companies for $520 per vial and for governments “of developed countries” around the world for $390 per vial. Gilead Sciences wants to offer pricing options for all economic classes for everyone to access including lower prices for government programs like Medicare.
This pharmaceutical company will be offering remdesivir to everyone whether or not have a patient has insurance with some uninsured to be covered under the provisions of the CARES Act. People who are privately insured will have out-of-pocket costs to be determined by certain insurance plans.
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance
"Under the company’s plans, Gilead will charge a higher price for patients with private insurance in the U.S., and a lower price for U.S. government health programs"
https://t.co/JZmEPP2Y0g— David Jolly (@DavidJollyFL) June 29, 2020
Gilead Sciences will provide remdesivir at a lower cost through agreements with generic manufacturers. A majority of patients being treated with remsesivir will need six vials over a five-day treatment plan. Prices for the five-day treatment will cost $3,120 for commercial insurance patients and $2,340 for government cost patients.
Some patients will require a longer, 10-day treatment and needed 11 vials that can cost $5,720 for a U.S. patient with private insurance or a patient with government costs of $4,290. Scientists are seeing success in recovery time treating severely ill COVID-19 patients with remdesivir, but the FDA has yet to officially approve any COVID-19 treatments.
This COVID-19 treatment is expected to save nearly $12,000 per patient due to early hospital discharge with recovery from the remdesivir treatment. Gilead Sciences is continuing testing and developing a better course of treatment for higher chances of recovery.
-
A transformative partnership to boost biodiversity, resilience, and gender equality in the face of climate change. The Philippines, in...
-
Claims by the ‘Crimea Combat Seagulls’ of poisoning two dozen Russian soldiers raise questions, prompting scrutiny and calls for...
-
According to the latest annual report from the Tokyo metropolitan government, Tokyo finds itself at the bottom of Japan’s...
-
A revealing look at the tensions, beliefs, and family dynamics within the British royal family In his latest book,...
-
A single-engine aircraft en route from the Czech Republic to Croatia crashes in western Austria, prompting an investigation into...
-
Historic Bust: Massive Counterfeit Coin Operation Exposed, Unveiling Unprecedented Scale of Fake Toonies in Canada. In a groundbreaking development,...
-
Global leaders from BRICS urge restraint, humanitarian truce, and diplomatic solutions to quell the Israel-Hamas tensions. In a landmark...
-
Secretary of State Antony Blinken calls for de-escalation as fighting displaces millions and raises concerns for upcoming Congo elections....
-
The government is taking action to stop the spread of the bloodsucking pests. The South Korean government has launched...
-
Landmark ruling highlights ongoing tax challenges for short-term rental platforms in Italy In a significant development, an Italian judge...
-
Deportation Deadline Sparks Humanitarian Worries in Pakistan Pakistan’s government announced on Monday that almost 200,000 Afghan nationals have voluntarily...
-
Lessons Learned Shape Taiwan’s Preparedness in a Changing World Taiwan’s military has embarked on a comprehensive initiative to strengthen...